Pharmacologic rescue of motivational deficit in an animal model of the negative symptoms of schizophrenia

Biological Psychiatry

Volumn 69, Issue 10, 2011, Pages 928-935

  Simpson, Eleanor H ^a   Kellendonk, Christoph ^a,b   Ward, Ryan D ^a   Richards, Vanessa ^a   Lipatova, Olga ^c   Fairhurst, Stephen ^a   Kandel, Eric R ^a,b,e,f   Balsam, Peter D ^a,d  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c UNIVERSITY OF VERMONT   (United States)

^d Barnard College of Columbia University   (United States)

^e HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^f Kavli Institute for Brain Science   (United States)

Author keywords

Animal model; D2 receptor; motivation; operant conditioning; schizophrenia; serotonin receptor 5 HT2C

Indexed keywords

DOPAMINE 2 RECEPTOR; SB 24280; SEROTONIN 2C ANTAGONIST; SEROTONIN 2C RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FATIGUE; MENTAL DISEASE; MOTIVATION DEFICIT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REWARD; SATIETY; SCHIZOPHRENIA;

AFFECTIVE SYMPTOMS; AMINOPYRIDINES; ANALYSIS OF VARIANCE; ANIMALS; CONDITIONING, OPERANT; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; GENE EXPRESSION; INDOLES; MICE; MICE, TRANSGENIC; MOTIVATION; RECEPTOR, SEROTONIN, 5-HT2C; RECEPTORS, DOPAMINE D2; REWARD; SCHIZOPHRENIA; SEROTONIN 5-HT2 RECEPTOR ANTAGONISTS; UP-REGULATION;

EID: 79955473823     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2011.01.012     Document Type: Article

References (39)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 4th ed. 1994 American Psychiatric Press Washington, DC
2. D.E. Gard, A.M. Kring, M.G. Gard, W.P. Horan, and M.F. Green Anhedonia in schizophrenia: Distinctions between anticipatory and consummatory pleasure Schizophr Res 93 2007 253 260 (Pubitemid 46817952)
3. J.M. Gold, J.A. Waltz, K.J. Prentice, S.E. Morris, and E.A. Heerey Reward processing in schizophrenia: A deficit in the representation of value Schizophr Bull 34 2008 835 847
4. H. Ziauddeen, and G.K. Murray The relevance of reward pathways for schizophrenia Curr Opin Psychiatry 23 2010 91 96
5. K.S. Smith, and K.C. Berridge Opioid limbic circuit for reward: Interaction between hedonic hotspots of nucleus accumbens and ventral pallidum J Neurosci 27 2007 1594 1605 (Pubitemid 46280077)
6. C. Kellendonk, E.H. Simpson, H.J. Polan, G. Malleret, S. Vronskaya, and V. Winiger Transient and selective overexpression of dopamine D2 receptors in the striatum causes persistent abnormalities in prefrontal cortex functioning Neuron 49 2006 603 615 (Pubitemid 43221894)
7. M. Mayford, M.E. Bach, Y.Y. Huang, L. Wang, R.D. Hawkins, and E.R. Kandel Control of memory formation through regulated expression of a CaMKII transgene Science 274 1996 1678 1683 (Pubitemid 26414891)
8. R.D. Ward, C. Kellendonk, E.H. Simpson, O. Lipatova, M.R. Drew, and S. Fairhurst Impaired timing precision produced by striatal D2 receptor overexpression is mediated by cognitive and motivational deficits Behav Neurosci 123 2009 720 730
9. M.E. Bach, E.H. Simpson, L. Kahn, J.J. Marshall, E.R. Kandel, and C. Kellendonk Transient and selective overexpression of D2 receptors in the striatum causes persistent deficits in conditional associative learning Proc Natl Acad Sci U S A 105 2008 16027 16032
10. M.R. Drew, E.H. Simpson, C. Kellendonk, W.G. Herzberg, O. Lipatova, and S. Fairhurst Transient overexpression of striatal D2 receptors impairs operant motivation and interval timing J Neurosci 27 2007 7731 7739 (Pubitemid 47093816)
11. J. Addington, D. Addington, and E. Maticka-Tyndale Cognitive functioning and positive and negative symptoms in schizophrenia Schizophr Res 5 1991 123 134
12. I. Berman, B. Viegner, A. Merson, E. Allan, D. Pappas, and A.I. Green Differential relationships between positive and negative symptoms and neuropsychological deficits in schizophrenia Schizophr Res 25 1997 1 10 (Pubitemid 27239625)
13. M.J. Bubar, P.K. Seitz, M.L. Thomas, and K.A. Cunningham Validation of a selective serotonin 5-HT (2C) receptor antibody for utilization in fluorescence immunohistochemistry studies Brain Res 1063 2005 105 113 (Pubitemid 41741021)
14. S.M. Stahl, and P.F. Buckley Negative symptoms of schizophrenia: A problem that will not go away Acta Psychiatr Scand 115 2007 4 11 (Pubitemid 44973546)
15. S. Kapur, S.C. VanderSpek, B.A. Brownlee, and J.N. Nobrega Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: A suggested solution based on in vivo occupancy J Pharmacol Exp Ther 305 2003 625 631 (Pubitemid 36459179)
16. D.V. Naiker, S.V. Catts, V.S. Catts, K.S. Bedi, and L.J. Bryan-Lluka Dose determination of haloperidol, risperidone and olanzapine using an in vivo dopamine D2-receptor occupancy method in the rat Eur J Pharmacol 540 2006 87 90 (Pubitemid 43866708)
17. T. Karl, L. Duffy, E. O'Brien, I. Matsumoto, and I. Dedova Behavioural effects of chronic haloperidol and risperidone treatment in rats Behav Brain Res 171 2006 286 294 (Pubitemid 43946503)
18. P. Turrone, G. Remington, S. Kapur, and J.N. Nobrega Differential effects of within-day continuous vs. transient dopamine D2 receptor occupancy in the development of vacuous chewing movements (VCMs) in rats Neuropsychopharmacology 28 2003 1433 1439 (Pubitemid 41070877)
19. T.C. Manschreck, and R.A. Boshes The CATIE schizophrenia trial: Results, impact, controversy Harv Rev Psychiatry 15 2007 245 258 (Pubitemid 47557208)
20. A.M. Mortimer Cognitive function in schizophrenia - do neuroleptics make a difference? Pharmacol Biochem Behav 56 1997 789 795 (Pubitemid 27189765)
21. J.D. Salamone, M. Correa, A. Farrar, and S.M. Mingote Effort-related functions of nucleus accumbens dopamine and associated forebrain circuits Psychopharmacology (Berl) 191 2007 461 482 (Pubitemid 46355902)
22. D.M. Barch The cognitive neuroscience of schizophrenia Annu Rev Clin Psychol 1 2005 321 353 (Pubitemid 43843954)
23. D.J. Surmeier, J. Ding, M. Day, Z. Wang, and W. Shen D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons Trends Neurosci 30 2007 228 235 (Pubitemid 46654239)
24. D.J. Surmeier, A. Reiner, M.S. Levine, and M.A. Ariano Are neostriatal dopamine receptors co-localized? Trends Neurosci 16 1993 299 305 (Pubitemid 23190644)
25. J. Bertran-Gonzalez, C. Bosch, M. Maroteaux, M. Matamales, D. Herve, E. Valjent, and J.A. Girault Opposing patterns of signaling activation in dopamine D1 and D2 receptor-expressing striatal neurons in response to cocaine and haloperidol J Neurosci 28 2008 5671 5685
26. K.W. Lee, Y. Kim, A.M. Kim, K. Helmin, A.C. Nairn, and P. Greengard Cocaine-induced dendritic spine formation in D1 and D2 dopamine receptor-containing medium spiny neurons in nucleus accumbens Proc Natl Acad Sci U S A 103 2006 3399 3404 (Pubitemid 43346480)
27. K. Herrick-Davis, E. Grinde, and M. Teitler Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine 2C receptors J Pharmacol Exp Ther 295 2000 226 232
28. H.Y. Meltzer, and M. Huang In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems Prog Brain Res 172 2008 177 197
29. P.J. Fletcher, M. Tampakeras, J. Sinyard, A. Slassi, M. Isaac, and G.A. Higgins Characterizing the effects of 5-HT (2C) receptor ligands on motor activity and feeding behaviour in 5-HT(2C) receptor knockout mice Neuropharmacology 57 2009 259 267
30. V. Di Matteo, A. De Blasi, C. Di Giulio, and E. Esposito Role of 5-HT (2C) receptors in the control of central dopamine function Trends Pharmacol Sci 22 2001 229 232 (Pubitemid 32411523)
31. L. Abdallah, S.J. Bonasera, F.W. Hopf, L. O'Dell, M. Giorgetti, and M. Jongsma Impact of serotonin 2C receptor null mutation on physiology and behavior associated with nigrostriatal dopamine pathway function J Neurosci 29 2009 8156 8165
32. K.A. Berg, J.D. Cropper, C.M. Niswender, E. Sanders-Bush, R.B. Emeson, and W.P. Clarke RNA-editing of the 5-HT (2C) receptor alters agonist-receptor-effector coupling specificity Br J Pharmacol 134 2001 386 392 (Pubitemid 32989136)
33. M.S. Sodhi, P.W. Burnet, A.J. Makoff, R.W. Kerwin, and P.J. Harrison RNA editing of the 5-HT (2C) receptor is reduced in schizophrenia Mol Psychiatry 6 2001 373 379 (Pubitemid 32566085)
34. S. Dracheva, S.L. Elhakem, S.M. Marcus, L.J. Siever, S.R. McGurk, and V. Haroutunian RNA editing and alternative splicing of human serotonin 2C receptor in schizophrenia J Neurochem 87 2003 1402 1412 (Pubitemid 38020574)
35. S. Dracheva, N. Patel, D.A. Woo, S.M. Marcus, L.J. Siever, and V. Haroutunian Increased serotonin 2C receptor mRNA editing: A possible risk factor for suicide Mol Psychiatry 13 2008 1001 1010
36. M.J. Millan Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: Focus on novel therapeutic strategies Therapie 60 2005 441 460
37. S. Rosenzweig-Lipson, J. Dunlop, and K.L. Marquis 5-HT2C receptor agonists as an innovative approach for psychiatric disorders Drug News Perspect 20 2007 565 571 (Pubitemid 351480207)
38. P.J. Fletcher, A.F. Chintoh, J. Sinyard, and G.A. Higgins Injection of the 5-HT2C receptor agonist Ro60-0175 into the ventral tegmental area reduces cocaine-induced locomotor activity and cocaine self-administration Neuropsychopharmacology 29 2004 308 318 (Pubitemid 38175149)
39. M.J. Bubar, and K.A. Cunningham Prospects for serotonin 5-HT2R pharmacotherapy in psychostimulant abuse Prog Brain Res 172 2008 319 346